LabTurbo Biotech Corporation
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
End-to-end, fully automated precision medicine genetic testing systems, reagent kits, and testing services.
(The content above was translated by AI.)
(The content above was translated by AI.)
Founded Year
2019
Unified Business No.
82901149
Status
Active
Number of Employees
0
Total Paid-in
Capital
483,266,330 (NT$)
Location of Company
Taiwan
, Taipei City
Exit Status
Emerging Stock Exchange(2023)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
LabTurbo Biotech Corporation was established in June 2019. It is primarily engaged in the research and development, production, and sales of nucleic acid extraction, genetic testing, genetic testing reagents, and instruments, as well as the operation of sports science venues. Currently, its main products and services include fully automated, full-process precision medical genetic testing systems and reagent kits, as well as testing services.
LabTurbo Biotech Corporation is based in Taiwan with a global footprint and is committed to technological innovation. In 2023, it was approved as a biotechnology and pharmaceutical company by the Ministry of Economic Affairs under the "Act for the Development of Biotech and Pharmaceutical Industry." Its developed product, LabTurbo AIO, has passed Taiwan's A.2570 clinical multi-target detection system instrument IVD medical device certification. During the COVID-19 pandemic, the company provided various medical units with high-throughput, accurate, and real-time qPCR testing results, earning high praise and trust. LabTurbo Biotech Corporation is highly competitive internationally. Its subsidiary, Huijing Biotechnology Co., Ltd., derives 80% of its revenue from overseas markets. Its US subsidiary, LabTurbo Biotech LLC, has established a CLIA-licensed medical testing center. In addition to coordinating with local medical insurance reimbursements for testing, it also manages distribution channels and sales in Europe and the United States, and assists the parent company in obtaining FDA 510(k) clearance for its in vitro diagnostic systems and reagent kits. LabTurbo Biotech Corporation recently developed the QuadAIO point-of-care testing (POCT) system, which passed the Ministry of Economic Affairs' "A+ Industrial Innovation R&D Program" at the end of 2021. This is expected to expand the scope of applicable specimens and increase the volume of genetic testing, thereby enhancing its product share and market share in the POCT market.
(The content above was translated by AI.)
LabTurbo Biotech Corporation is based in Taiwan with a global footprint and is committed to technological innovation. In 2023, it was approved as a biotechnology and pharmaceutical company by the Ministry of Economic Affairs under the "Act for the Development of Biotech and Pharmaceutical Industry." Its developed product, LabTurbo AIO, has passed Taiwan's A.2570 clinical multi-target detection system instrument IVD medical device certification. During the COVID-19 pandemic, the company provided various medical units with high-throughput, accurate, and real-time qPCR testing results, earning high praise and trust. LabTurbo Biotech Corporation is highly competitive internationally. Its subsidiary, Huijing Biotechnology Co., Ltd., derives 80% of its revenue from overseas markets. Its US subsidiary, LabTurbo Biotech LLC, has established a CLIA-licensed medical testing center. In addition to coordinating with local medical insurance reimbursements for testing, it also manages distribution channels and sales in Europe and the United States, and assists the parent company in obtaining FDA 510(k) clearance for its in vitro diagnostic systems and reagent kits. LabTurbo Biotech Corporation recently developed the QuadAIO point-of-care testing (POCT) system, which passed the Ministry of Economic Affairs' "A+ Industrial Innovation R&D Program" at the end of 2021. This is expected to expand the scope of applicable specimens and increase the volume of genetic testing, thereby enhancing its product share and market share in the POCT market.
(The content above was translated by AI.)
